Genedx Holdings CORP 8-K filings

GeneDx Holdings Corp. announced its second quarter 2026 financial results, highlighting an 11% year-over-year revenue increase to $114.4 million and a 32% surge in exome and genome test volume.

GeneDx Holdings Corp. announced the appointment of Mark Gardner as President, effective June 15, 2026, to lead commercial and operations teams.

GeneDx Holdings Corp. announced its first quarter 2026 financial results, reporting revenue growth and updating its full-year guidance with a focus on profitability.

GeneDx Holdings Corp. entered a new $100 million term loan agreement with Blackstone, repaying its previous debt and aiming for balance sheet optimization.

GeneDx Holdings Corp. reported robust fourth quarter and full year 2025 financial results, surpassing revenue guidance and reaffirming strong growth projections for 2026 driven by exome and genome testing.

GeneDx Holdings Corp. announced preliminary 2025 financial results at the high end of or exceeding guidance and issued robust growth projections for 2026.

GeneDx Holdings Corp. reported robust third-quarter 2025 financial results, exceeding expectations with significant revenue growth and increased full-year guidance, driven by strong demand for genomic testing.

GeneDx Holdings Corp. expanded its Board of Directors to eight members with the immediate appointment of Dr. Thomas Fuchs, SVP and Chief AI Officer at Eli Lilly and Company, as a Class I director.

GeneDx Holdings Corp. reported robust second quarter 2025 financial results, exceeding $100 million in revenue and achieving its fourth consecutive profitable quarter, leading to a significant increase in its full-year 2025 financial guidance.

GeneDx Holdings Corp. announced that its stockholders approved the re-election of two Class I directors and ratified Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025, at its Annual Meeting held on June 18, 2025.

GeneDx reports a successful first quarter in 2025 with significant revenue growth, profitability, and the announcement of the acquisition of Fabric Genomics, leading to raised full-year revenue guidance.

GeneDx is set to acquire Fabric Genomics for up to $51 million, combining their rare disease data with Fabric's AI platform to decentralize genomic testing globally.

GeneDx announces impressive financial results for Q4 and full year 2024, driven by significant revenue growth and margin expansion, and provides optimistic guidance for 2025.

GeneDx reports preliminary 2024 financial results, exceeding previous guidance with full-year revenue of at least $299 million and adjusted gross margin of at least 64%.

GeneDx has appointed Bryan Dechairo as its new Chief Operating Officer, effective immediately, to oversee key operational areas and drive the company's growth strategy.

GeneDx reported a profitable third quarter in 2024, driven by strong revenue growth in exome and genome testing, and has raised its full-year revenue guidance.

GeneDx announced a 52% year-over-year revenue increase in Q2 2024, driven by a 77% growth in exome and genome test revenue, and raised its full-year revenue guidance.

GeneDx Holdings Corp. held its annual meeting on June 20, 2024, where stockholders voted to elect three Class III directors and ratify the appointment of Ernst & Young LLP as the company's auditor.

GeneDx Holdings Corp. has entered into a sales agreement to offer and sell up to $75 million of its Class A common stock through an at-the-market offering.

GeneDx announced a strong first quarter in 2024 with significant revenue growth, improved margins, and reduced cash burn, leading to an increased full-year revenue guidance.

GeneDx reported a strong fourth quarter in 2023 with significant revenue growth and margin expansion, and issued positive guidance for 2024, reiterating their path to profitability in 2025.